- Home
- Search Results
Search Results
Filter :
FILTER BY keyword:
FILTER BY author:
- Manish Barman [2]
- Mohamedali Gaafar [2]
- Muhammad Sharif [2]
- Abdul Rahman Mustafa [1]
- Ahmad Eid Nazzal Alharafsheh [1]
- Bassem Al Hariri [1]
- Harman Talat Saman [1]
- Hatem Abuswiril [1]
- Israa Amjed [1]
- Junaid Abu [1]
- M.N. Illahi [1]
- Magdi Hassan [1]
- Memon Noor Illahi [1]
- Mohamed Abou Kamar [1]
- Muayad Kasem Khaled Ahmad [1]
- Naseem Ambra [1]
- S. Hamuda [1]
- Tanweer Hussain [1]
- [+] More [-] Less
FILTER BY language:
FILTER BY content type:
FILTER BY publication:
FILTER BY affiliation:
- Clinical Medicine, Weill Cornell Medicine-Qatar, Doha, Qatar. [1]
- Communicable Disease Center, Hamad Medical Corporation, Doha, Qatar. [1]
- Department of Clinical Medicine, Weill Cornell Medicine, Qatar [1]
- Department of Medicine, Hamad Medical Corporation, Doha, Qatar E-mail: [email protected] [1]
- Hamad Medical Corporation, Doha, Qatar. [1]
- Medicine Department, Hamad Medical Corporation, Doha, Qatar. E-mail: [email protected] [1]
FILTER BY article type:
FILTER BY access type:
Embracing healthcare delivery challenges during a pandemic. review from a nodal designated COVID-19 center in qatar
Hospitals and healthcare systems are instrumental in the formulation and delivery of a coordinated response to disaster management especially epidemics. In healthcare policy and strategy formation there are only trade-offs which with uncertainty are akin to gambles. National organizations play a key role in pandemics through the expression of physician motivation. Effective strategies can facilitate physician action through economies of scale that lower the costs for physicians to meet both community and patients' needs. Moreover no matter how well clinicians are motivated and positioned to act their collective actions are likely to fall short without complementary systems for population-based care that require the operational support of an organization. This review of institutional policy implementation and frameworks intends to highlight how a nodal-designated COVID-19 center in Qatar managed to control the menace by altering its procedural sets and work arrangements to augment an integrated intrinsic response to a briskly emerging conceivably complex situation. This outcome was achieved under the guidance of a national leadership team effectively adapted to its specific challenges by building on current medical evidence management routines proficiencies and health system capacity. This ambitious drive started with the cohesion of services and implementation of evidence-based protocols by assigning a physician-led team to research strategize and organize improved patient flow and information by arranging analytical compliance and preparedness. Through these service approaches and ongoing efforts HMGH has realized significant outcome improvements such as increasing capacity building reducing healthcare waste and increasing patient satisfaction rates whilst successfully achieving significantly lower COVID-19 mortality both in terms of absolute numbers and as percent population compared to many developed countries in the world. The strategies outlined in this article might not be all-inclusive or fit other healthcare system models but they generate a veritable interest to pursue and be subjected to further rigorous study.
Ceftriaxone-induced hepatotoxicity in patients with common medical infections in Qatar: A retrospective study
Introduction: Ceftriaxone a third-generation cephalosporin is frequently used for the treatment of various bacterial infections as a broad-spectrum antibiotic for many decades. Although ceftriaxone is a well-tolerated drug in most cases it can lead to serious liver injury which can be a real challenge to the treating physician. Given the potentially serious adverse effects that can vary from mild biochemical abnormalities to complete liver failure we intend to assess the spectrum of liver injury based on biochemical criteria for patients treated with ceftriaxone for common bacterial infections in Qatar.Objectives: This study aimed to explore the incidence of ceftriaxone-induced liver injury at Hazm Mebaireek General Hospital Qatar and to evaluate the relationship of the ceftriaxone dose if any with liver dysfunction.Methods: This retrospective study included hospitalized adult patients treated with ceftriaxone at our hospital from January 2019 to December 2019 and analyzed demographic and clinical data obtained from electronic medical records. This study determined the incidence of liver injury (primary outcome) in patients treated with ceftriaxone (2 g/day) for ≥ 2 consecutive days by reviewing liver function test results until the day of discharge and at the first outpatient follow-up.
Results: The final data analysis included a total of 634 patients admitted and treated with ceftriaxone from January 2019 to December 2019.In the multivariate analysis with propensity score adjustment ceftriaxone was independently associated with liver injury especially when combined with other agents utilizing hepatic metabolism.Conclusions: Ceftriaxone was associated with a significantly higher incidence of liver injury (19.7%) when used along with other medications that are metabolized in the liver as found in the present study compared with other similar studies (approximately 2.9%–13.9%). Furthermore the incidence was too high to be ignored in clinical practice.